IREN proposes $875 million convertible notes offering due 2031
HORSHAM, Pa. - STRATA Skin Sciences, Inc. (NASDAQ:SSKN), a medical technology company with annual revenue of $32.8 million, is highlighting clinical evidence supporting its XTRAC Excimer Laser as an effective treatment for atopic dermatitis during Eczema Awareness Month. According to InvestingPro data, the company maintains a healthy gross profit margin of 58%, despite operating in a competitive medical device market.
The company noted that the American Medical Association has expanded excimer laser indications to include inflammatory and autoimmune skin diseases, enabling Medicare, Medicaid, and private payer reimbursement for atopic dermatitis treatment.
Atopic dermatitis affects more than 9.6 million children and 16.5 million adults in the United States, causing symptoms such as pain, fissures, and intense itching that impact daily living and emotional well-being.
"The excimer laser is one of our most effective treatments for localized eczema," said Dr. Mark G. Lebwohl, Dean for Clinical Therapeutics at Icahn School of Medicine at Mount Sinai.
Multiple peer-reviewed studies support the XTRAC laser’s effectiveness. A 2016 study published in the International Journal of Dermatology reported that patients with severe chronic hand and foot eczema experienced a 69% reduction in disease severity after approximately 13 sessions, with 87% achieving clear or almost clear skin. While the clinical results are promising, InvestingPro analysis indicates the company’s stock has faced challenges, declining 21% over the past six months. InvestingPro subscribers can access 6 additional key insights about SSKN’s financial health and market position.
The XTRAC system delivers targeted therapy to diseased skin while sparing healthy tissue, and is particularly effective for difficult-to-treat areas like hands and feet. The company states the treatment provides shorter regimens with rapid clearance and long-lasting remission compared to other options.
STRATA Skin Sciences offers the XTRAC excimer laser through its Partnership Program, which includes a fee-per-treatment cost structure rather than equipment purchase.
This article is based on a press release statement from STRATA Skin Sciences.
In other recent news, STRATA Skin Sciences has completed a registered direct offering, raising approximately $2.42 million in gross proceeds. The company sold 1,097,547 shares of common stock at $2.204 per share, with Ladenburg Thalmann & Co. Inc. acting as the exclusive placement agent. This financial move was conducted under a shelf registration statement previously declared effective by the Securities and Exchange Commission. Additionally, STRATA Skin Sciences reported promising results from a peer-reviewed study on its 308nm Excimer laser, used in combination with JAK inhibitors for vitiligo treatment. The study, published in the International Journal of Dermatology, indicated a 14.20% higher repigmentation rate compared to monotherapy and highlighted high pigmentation stability and a low relapse rate at a one-year follow-up. Moreover, the company’s E360 consulting program has shown to facilitate business growth for partner clinics using STRATA’s XTRAC excimer laser technology. This program provides marketing solutions, business system optimization, and patient retention strategies. These developments reflect STRATA Skin Sciences’ ongoing efforts to expand its market presence and enhance its dermatologic treatment offerings.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.